Phase 3 Readout

RNXT: Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following

Name: Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following
Start: 2027-09-01
End: 2027-09-01

September 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 1, 2027
Company: RenovoRx, Inc. (RNXT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following

September 1, 2027

RNXT overview →

Company: RenovoRx, Inc. (RNXT)
Indication: Locally Advanced Pancreatic Cancer